Comparing nab-paclitaxel and solvent-based paclitaxel in platinum-resistant ovarian cancer: evidence and perspectives

Despite the absence of direct trials, experts considered evidence sufficient to support nab-paclitaxel as a viable alternative to sb-paclitaxel in platinum-resistant ovarian cancer with comparable efficacy, safety, and fewer hypersensitivity reactions. Additional randomized trials were not deemed necessary.